On Monday, Mineralys Therapeutics, Inc. MLYS released topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN Phase 2 trials of lorundrostat for uncontrolled hypertension (uHTN) or resistant hypertension (rHTN).Both trials achieved statistical significance, were clinically meaningful in their prespecified primary efficacy endpoints, and demonstrated a favorable safety and tolerability profile.The Launch-HTN trial met the primary endpoint with lorundrostat 50 mg dose achieved a 16.9 mmHg red ...